Ardena expands capacity to satisfy Novavax COVID vaccine demand

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

How Early Regulatory Planning Saves Time and Money in Product Development

Incorporating early regulatory planning in product development can significantly...

America’s AI Action Plan Boosts Pharmaceutical Innovation

Accelerating Pharmaceutical and Biopharmaceutical Innovation through America’s AI Action...

Trump To Roll-Out 340B Drugs Discount Program in 2026

The Trump administration is going to pilot a voluntary...

60-Day Window by Trump for Firms to Lower Their Drug Prices

President Donald Trump of the USA has sent letters...

Ardena, a specialist pharmaceutical contract development and manufacturing organisation (CDMO), announced it will be expanding its capacity for purification and fractionation of GMP manufacturing at its site in Södertälje, Sweden. The expansion will satisfy long-term demand expected from Novavax for production of the company’s COVID-19 vaccine, among others.

The expansion comes following the grant of conditional marketing authorisation by the European Commission for Novavax’s COVID-19 vaccine, Nuvaxovid.

For 15 years, Ardena has been proud to partner with Novavax on the development of the fractionation process for their proprietary Matrix-M™ adjuvant, a key component of the vaccine. Only the fifth vaccine approved in Europe, Nuvaxovid is a recombinant protein-based vaccine co-formulated with Matrix-M adjuvant to enhance an immune response.

The expansion plan includes additional chromatography, tangential flow filtration and lyophilization capabilities.

Speaking of the plans Harry Christiaens, Ardena CEO, said: “This announcement will significantly enhance our ability to help Novavax deliver more vaccines. It makes me proud that our company is part of the continuing innovation and multiple partnerships going on worldwide to tackle COVID-19.”

Latest stories

Related stories

How Early Regulatory Planning Saves Time and Money in Product Development

Incorporating early regulatory planning in product development can significantly...

America’s AI Action Plan Boosts Pharmaceutical Innovation

Accelerating Pharmaceutical and Biopharmaceutical Innovation through America’s AI Action...

Trump To Roll-Out 340B Drugs Discount Program in 2026

The Trump administration is going to pilot a voluntary...

60-Day Window by Trump for Firms to Lower Their Drug Prices

President Donald Trump of the USA has sent letters...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back